Akimoto S, Akakura K, Shimazaki J
Department of Urology, School of Medicine, Chiba University.
Hinyokika Kiyo. 1988 Aug;34(8):1389-96.
The levels of prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) were determined in the serum of 200 untreated patients 28 patients with reactivated prostatic cancer and 179 patients with benign prostatic hypertrophy (BPH) from 1979 to 1987. PAP and gamma-Sm were determined using an Eiken and Chugai kit, respectively and PA was assayed using an Eiken or Travenol kit. The sensitivity of PAP, gamma-Sm and PA respectively in the untreated prostatic cancer cases was 0, 0% and 67%, for Stage A1, 25, 17 and 100% for Stage A2, 23, 50 and 60% for Stage B, 62, 81 and 94% in Stage C, 58, 67 and 90% for Stage D1, 86, 88 and 100% for Stage D2. The specificity of PAP, gamma-Sm and PA is 89, 69 and 43%, respectively. The efficiency of PAP was the highest at all stages as a whole, but when compared at each stage, gamma-Sm was the highest at Stages B and C. The sensitivity of simultaneous assays of PAP and gamma-Sm was slightly increased, but sensitivity was not increased by simultaneous use of three markers. The efficiency of a simultaneous assay was lower than that of a single assay with PAP. However, combined determination of gamma-Sm or PA with PAP was found to be useful for monitoring the clinical course of the reactivated patients. Correlation between PAP and PA levels was high, but that between gamma-Sm and PA levels was low. There was no correlation between PAP and gamma-Sm levels. In conclusion, PAP is the most valuable marker for prostatic cancer, and gamma-Sm is of value for use in combination with PAP. However, an additional PA assay was not found to be of advantage.
1979年至1987年期间，对200例未经治疗的患者、28例前列腺癌复发患者以及179例良性前列腺增生（BPH）患者的血清前列腺酸性磷酸酶（PAP）、γ-精浆蛋白（γ-Sm）和前列腺特异性抗原（PA）水平进行了测定。PAP和γ-Sm分别使用荣研和中外制药试剂盒进行测定，PA使用荣研或特拉文诺试剂盒进行测定。在未经治疗的前列腺癌病例中，PAP、γ-Sm和PA的敏感性分别为：A1期0%、0%和67%；A2期25%、17%和100%；B期23%、50%和60%；C期62%、81%和94%；D1期58%、67%和90%；D2期86%、88%和100%。PAP、γ-Sm和PA的特异性分别为89%、69%和43%。总体而言，PAP在所有阶段的效率最高，但在各阶段进行比较时，γ-Sm在B期和C期最高。同时检测PAP和γ-Sm的敏感性略有提高，但同时使用三种标志物并未提高敏感性。同时检测的效率低于单独检测PAP的效率。然而，发现γ-Sm或PA与PAP联合测定对于监测复发患者的临床病程是有用的。PAP和PA水平之间的相关性较高，但γ-Sm和PA水平之间的相关性较低。PAP和γ-Sm水平之间无相关性。总之，PAP是前列腺癌最有价值的标志物，γ-Sm与PAP联合使用有价值。然而，额外检测PA未发现有优势。
